ASTRO Urges EviCore to Restore Low-Dose Radiation Coverage

The radiation oncology group is pressing the insurer to reverse policy changes that restrict treatment for several benign conditions.

Updated on Nov. 20, 2026 in Cancer

Isometric editorial illustration of a bare curved radiation treatment gantry arc with a single beam line, in oxblood, teal, and cream, evoking the coverage dispute over low-dose radiation therapy.
The American Society for Radiation Oncology asked EviCore Healthcare on November 6 to restore low-dose radiation coverage for several benign conditions as a Florida lawsuit challenges the policy. AI Illustration. Upload story photo >

Live Poll

Should insurers be able to stop covering treatments that doctors still recommend?

The American Society for Radiation Oncology (ASTRO) has asked EviCore Healthcare to restore access to low-dose radiation therapy (LDRT) for benign conditions after the insurer revised its guidelines. The Radiotherapy Access Alliance separately filed a lawsuit in Florida on November 4 challenging the policy.

Why it matters

EviCore's revised guidelines would classify LDRT for osteoarthritis, plantar fasciitis and trochanteric bursitis as not medically necessary, potentially limiting treatment options for patients with these conditions. ASTRO argues the changes attempt to unilaterally alter existing provider contracts and reduce payments for care.

The revised EviCore guidelines cover three specified benign conditions, and the policy is being challenged in a pending Florida civil lawsuit. It is not yet clear whether the insurer will modify the policy before ASTRO completes its own clinical practice guideline.

The players

EviCore Healthcare

EviCore Healthcare is a utilization management company that manages specialty medical benefits, including radiation oncology, for health plans.

American Society for Radiation Oncology (ASTRO)

ASTRO is the largest professional society of radiation oncology physicians, physicists, nurses and other clinicians in the United States.

The details

ASTRO CEO Vivek Kavadi, MD, sent a letter to EviCore dated November 6, following an October 22 meeting with EviCore leadership. In the letter, ASTRO asked the insurer to keep its step-therapy pathway in place until ASTRO publishes its LDRT clinical practice guideline, which will define which conservative therapies patients should try first and set a minimum symptom duration.

Timeline

  1. October 22: ASTRO met with EviCore leadership.

  2. November 4: The Radiotherapy Access Alliance filed a lawsuit in Florida challenging EviCore's LDRT policy.

  3. November 6: ASTRO sent a letter to EviCore asking it to restore LDRT coverage.

  4. Early 2027: ASTRO expects to publish its LDRT clinical practice guideline.

Health Landscape

The dispute reflects a broader pattern in which specialty benefit managers such as EviCore use prior-authorization and step-therapy rules to narrow coverage for certain treatments. Providers like ASTRO increasingly contest these rules as contract changes that reduce payments and limit access.

Patients with osteoarthritis, plantar fasciitis or trochanteric bursitis may find low-dose radiation therapy harder to obtain if EviCore's revised guidelines take effect. Those patients may first be required to complete conservative therapies under the insurer's step-therapy pathway.

The takeaway

Patients considering radiation therapy for benign conditions should check with their insurer about current coverage rules and any step-therapy requirements before scheduling treatment.

What happens next

ASTRO expects to publish its LDRT clinical practice guideline in early 2027, which will define first-line conservative therapies and minimum symptom durations.

Further reading

Explore more on Cancer coverage and treatment developments.

Source note: This article includes information reported by AuntMinnie.

Live Poll

Should insurers be able to stop covering treatments that doctors still recommend?